Secondary findings from clinical genomic sequencing: prevalence, patient perspectives, family history assessment, and health-care costs from a multisite study

[1]  Robert C. Green,et al.  Short Term Costs of Integrating Whole Genome Sequencing into Primary Care and Cardiology Settings: A Pilot Randomized Trial , 2018, Genetics in Medicine.

[2]  Jeffrey W. Pennington,et al.  Anticipated responses of early adopter genetic specialists and nongenetic specialists to unsolicited genomic secondary findings , 2018, Genetics in Medicine.

[3]  R. Myers,et al.  Genomic sequencing identifies secondary findings in a cohort of parent study participants , 2017, Genetics in Medicine.

[4]  Muin J. Khoury,et al.  Cascade Screening for Familial Hypercholesterolemia and the Use of Genetic Testing. , 2017, JAMA.

[5]  Matthew S. Lebo,et al.  The Impact of Whole-Genome Sequencing on the Primary Care and Outcomes of Healthy Adult Patients: A Pilot Randomized Trial. , 2017, Annals of internal medicine.

[6]  Marylyn D. Ritchie,et al.  Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study , 2016, Science.

[7]  D. Nickerson,et al.  Design of a randomized controlled trial for genomic carrier screening in healthy patients seeking preconception genetic testing , 2016, Contemporary clinical trials.

[8]  W. Chung,et al.  Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics , 2016, Genetics in Medicine.

[9]  R. Green,et al.  Aggregate penetrance of genomic variants for actionable disorders in European and African Americans , 2016, Science Translational Medicine.

[10]  R. Myers,et al.  Genomic diagnosis for children with intellectual disability and/or developmental delay , 2016, bioRxiv.

[11]  Joseph S. Salama,et al.  Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. , 2016, American journal of human genetics.

[12]  R. Gibbs,et al.  Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors. , 2016, JAMA oncology.

[13]  Sarah M. Hartz,et al.  Identification of Medically Actionable Secondary Findings in the 1000 Genomes , 2015, PloS one.

[14]  M. Pletcher,et al.  Economic evidence on identifying clinically actionable findings with whole-genome sequencing: a scoping review , 2015, Genetics in Medicine.

[15]  H. Rehm,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[16]  Avni Santani,et al.  Actionable exomic incidental findings in 6503 participants: challenges of variant classification , 2015, Genome research.

[17]  Gail P Jarvik,et al.  The cost-effectiveness of returning incidental findings from next-generation genomic sequencing , 2014, Genetics in Medicine.

[18]  Magalie S Leduc,et al.  Molecular findings among patients referred for clinical whole-exome sequencing. , 2014, JAMA.

[19]  Peter Tarczy-Hornoch,et al.  Comparative effectiveness of next generation genomic sequencing for disease diagnosis: design of a randomized controlled trial in patients with colorectal cancer/polyposis syndromes. , 2014, Contemporary clinical trials.

[20]  Leslie G Biesecker,et al.  Diagnostic clinical genome and exome sequencing. , 2014, The New England journal of medicine.

[21]  Isaac S Kohane,et al.  The MedSeq Project: a randomized trial of integrating whole genome sequencing into clinical medicine , 2014, Trials.

[22]  E. Birney,et al.  Policy challenges of clinical genome sequencing , 2013, BMJ.

[23]  Kristy Lee,et al.  The NCGENES project: exploring the new world of genome sequencing. , 2013, North Carolina medical journal.

[24]  Robert C. Green,et al.  Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium , 2013, Genetics in Medicine.

[25]  Emily H Turner,et al.  Actionable, pathogenic incidental findings in 1,000 participants' exomes. , 2013, American journal of human genetics.

[26]  B. Knoppers,et al.  Recommendations for returning genomic incidental findings? We need to talk! , 2013, Genetics in Medicine.

[27]  Marc S. Williams,et al.  ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing , 2013, Genetics in Medicine.

[28]  Larry N. Singh,et al.  Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes. , 2012, American journal of human genetics.

[29]  Jonathan D. Eisenberg,et al.  The economic burden of incidentally detected findings. , 2011, Radiologic clinics of North America.

[30]  Nancy F. Hansen,et al.  The ClinSeq Project: piloting large-scale genome sequencing for research in genomic medicine. , 2009, Genome research.

[31]  R. Altman,et al.  The incidentalome: a threat to genomic medicine. , 2006, JAMA.

[32]  J. Haddow,et al.  Recommendations from the EGAPP Working Group: Routine testing for Factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members , 2011, Genetics in Medicine.